A Selective impairment of the IL-2 system in lymphocytes of patients with glioblastomas: Increased level of soluble IL-2R and reduced protein tyrosine phosphorylation

NeuroImmunoModulation

Volumn 4, Issue 1, 1997, Pages 49-56

  Ashkenazi, Ely ^a   Deutsch, Motti ^b   Tirosh, Reuven ^b   Weinreb, Arie ^a   Tsukerman, Alexander ^c   Brodie, Chava ^c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b Jerome Schottenstein Cellscan Center for Early Detection of Cancer   (Israel)

^c BAR ILAN UNIVERSITY   (Israel)

Author keywords

Brain tumors; Cytokines; Interleukin 2 receptor; Lymphocytes; Soluble receptor; Tyrosine phosphorylation

Indexed keywords

INTERLEUKIN 2 RECEPTOR; RECEPTOR SUBUNIT;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; GLIOBLASTOMA; HUMAN; IMMUNOCOMPETENCE; IMMUNOREACTIVITY; IMMUNOREGULATION; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR DENSITY; T LYMPHOCYTE;

EID: 0030885032     PISSN: 10217401     EISSN: 14230216     Source Type: Journal    
DOI: 10.1159/000097315     Document Type: Article

References (34)

1. Brooks WH, Netsky MG, Honvitz DA, Nor-mansell DE: Ccll-mcdiaied immunity in patients with primary brain tumors, J Exp Med 1972;136:1631-1647.
2. Roszman TL, Brooks WH, Steele C, Elliott L: Pokeweed mitogen-induced immunoglobulin secretion by peripheral blood lymphocytes from patients with primary intracranial tumors, Characterization of T helper and B cell function, J Immunol 1985:134:1545-1550.
3. Roszman TL, Brooks WH: Immunobiology of primary intracranial tumors, III, Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumors, Clin Exp Immunol 1980;39:395-402.
4. Roszman TL, Brooks WH, Elliott LH: Immunobiology of primary intracranial tumors, IV, Suppressor cell function and lectin binding lymphocyte subpopulation in patients with cerebral tumors, Cancer 1982:50:1273-1279.
5. Elliott LH, Brooks WH, Roszman TL: Cytoki-netic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors, J Immunol 1983:132:1208-1215.
6. Brooks WH, Roszman TL, Rogers, AS: Impairment of rosette-forming T lymphocytes in patients with primary intracranial tumors, Cancer 1976:37:1869-1873.
7. Micscher S, Whiteside TK, Careel S, von Fliedner V: Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: Effects of tumor cells and their supernatants 011 proliferative response of lymphocytes, J Immunol 1985:134:1640-1643.
8. Elllotl LH, Brooks WH, Roszman TL: Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin receptors, J Clin Invest 1990:86:80-86.
9. Elliott LH, Brooks WH, Roszman TL: Suppression of high affinity 1L-2 receptors on mitogen activated lymphocytes by glioma-derived suppressor factors, J Neurooncol 1992:14:1-7.
10. Maxwell M, Galanopoulos T, Ncville-Goldcn J, Antoniades N: Efïccl of the expression of transforming growth faclor-p2 in primary' human glioblastomas on immunosuppression and loss of immune surveillance, J Neurosurg 1992: 76:799-804.
11. Fontana A, Hengartncr H, de Tribolct N, Weber E: Glioblastoma cells release interleukin I and factors inhibiting IL-2-mcdialcd effects, J Immunol 1984;132:1837-1844.
12. Kumagai N, Benedict SH, Mills GB, Gelfand EW: Induction of competence and progression signals in human T lymphocytes by phorbol esters and calcium ionophores, J Cell Phvsiol 1988:137:329-336.
13. Churcher Y, Moss SE: Modulation of protein tyrosine phosphorylation during G I/S transition in activated human T-lvmphoblasts, J Biol Chem 1993:268:26144-26149.
14. Smith KA: lnterleukin-2: Inception, impact and implications, Science 1988:240:1169-1172.
15. Brodie C, Rcnz H, Bradelv K, Gelfand EW: NGF and anti-CD40 provide opposite signals to IgE production in IL-4 treated lymphocytes, F.urJ Immunol 1996:26:171-178.
16. Far DF, Peyron JF, Imbert V, Rossi B: Immu-nofluoresccnt quantification of tyrosine phosphorylation of cellular proteins in whole cells by flow cytometry, Cytometry 1994:15:327-334.
17. Taniguchi T, Matsui H, Fujita T, Hatakevama M, Kashima N, Fuse A, Hamuro J, Nishi-Takaoka C, Yamada G: Molecular analysis of the interleukin-2 system, Immunol Rev 1986: 92:120-197.
18. Appleby MW, Gross J A, Cooke MP, Levin SD, Qian X, Perlmuter RM: DefectiveTcell receptor signaling in mice lacking the thymic isoform of p58fyn, Cell 1992;70:751-763.
19. Roszman T, Elliott, L, Brooks, W: Modulation of T-cell function by gliomas, Immunol Today 1991:12:370-374.
20. Schwyzcr M, Fontana A: Partial purification and biochemical characterization of a T cell suppressor factor produced by human glioblastoma cells, J Immunol 1985:134:1003-1010.
21. Sicpl C, Bodmer S, Frei K, MacDonald HR, De Martin R, Hofer E, Fontanat A: The glioblastoma-derived T cell suppressor factor/transforming growth factor-p2 inhibits T cell growth without affecting the interaction of interleukin 2 with its receptor, Eur J Immunol 1982; 18: 593-600.
22. Wagner DK, York-Jolley J, Malek TR, Berzofsky JA, Nelson DL: Antigen-specific murine T cell clones produce soluble intcrleukin-2 receptor on stimulation with specific antigens, J Immunol 1986;137:592-596.
23. Noguchi M, Adelstcin S, Chao X, Leonard WJ: Characterization of the human interleukin receptor y chain gene, J Biol Chem 1993:268: 13601.
24. Nakari T, Robertson MJ, Streuli M, Zining W, Ciardelli TL, Smith KA, Ritz J: Interleukin 2 receptor y chain expression on resting and activated lymphoid cells, J Exp Med 1994:80:241-251.
25. Arima N, Kamio M, Okuma M, Ju G, Uchiya-ma T: The IL-2 receptor u-chain alters binding of IL-2 to the p-chain, J Immunol 1991:147: 3396-3401.
26. Nakamura Y, Russel SM, Mess SA, Friedman M, Erdos M, Francois C, Jacques Y, Adelstcin S, Leonard WJ: Heterodimcrization of the IL-2 receptor p-and y-chain cytoplasmic domains is required for signaling, Nature 1994:369:330-333.
27. Lowcnthal JW, Corthsey P, Tougnc C, Lees R, MacDonald HR, Nabholz M: High and low affinity IL-2 receptors: Analysis by IL-2 dissociation rate and reactivity with monoclonal anti-receptor antibody PC6L J Immunol 1985: 135:3988-3994.
28. Gutgsell NS, Malek TR: Formation of high affinity IL-2 receptor is dependent on a nonligand binding region of the a subunit, J Immunol 1994;153:3899-3907.
29. Rubin LA, Kurman CC, Fritz ME, Biddison WF, Boutin B, Yarchoan R, Nelson DL: Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro, J Immunol 1985;135:3172-3177.
30. Robb RJ, Kulny RM: Structure-function relationships for the IL-2 receptor system, IV, Analysis of the sequence and ligand binding properties of soluble Tac protein, J Immunol 1987;139:855-862.
31. Diamcnstcin T, Osawa H, Mouzaki A, Josi-movic-Alasevic O: Regulation of interleukin-2 receptor expression and receptor release, Mol Immunol 1986;23:1165-1172.
32. Rubin LA, Gay G, Nelson DL: The released interleukin 2 receptor binds interleukin 2 efficiency, J Immunol 1986;137:3841-3846.
33. Taicb J, Vittc-Mony V, Auffrcdou MT, Dorseuil GC, Bertoglio J, Vazquez AJ: Regulation of p56lck kinase expression and control of DNA synthesis in activated human B lymphocytes, J Biol Chem 1993:268:9169-9178.
34. Wang Z, Zhongeheng Z, Lanvin S, Xinyuan L: Substitution at the Glu62 residue of tile human intcrlcukin-2 differentially affects its binding to the a chain and the py complex of the intcr-leukin-2 receptor, Eur J Immunol 1995:25: 1212-1216.